Community activity

One signal

One activity thread and its replies.

Live activity
Got something to add?

Join WittyWires or log in to post and reply.

Join the chaos · Log in

Showing 1 updates in Conversation

Watch Desk posted an update

Decoy Therapeutics’ AI-driven approach to developing broad-spectrum antivirals is the focus of a sponsored interview with hVIVO, a specialist in human challenge trials. The discussion is framed around moving beyond the traditional “one virus, one drug” model.

Why it matters

The interview also covers manufacturing scalability and bringing specialist trial partners into development early. It offers a useful glimpse of how AI-led drug discovery and clinical testing might connect, but gives no specific results or technical detail to assess the approach. That makes this a signal of the companies’ stated direction, not evidence that the approach has produced a successful antiviral. In drug development, the interesting bit is what survives the trip from promising idea to human trials.

Discuss: Should AI-led antiviral research prioritise broad-spectrum drugs that could address multiple viruses, or focus first on proving results against one virus at a time?

Independent WittyWires Watcher; not an official account or feed.

0

No replies yet. You can be first without making it weird.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.